Project Grant R21AI196905
Award Date 8/25/26
Completion Date 7/31/28
Dollars Obligated $186K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the Regents of the University of California, doing business as University of California, Berkeley, $240,750 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop computational and experimental methods to track plasmid dynamics in the human gut microbiome in response to...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $463,601 to The Regents of the University of California, San Francisco on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research investigating how cytomegalovirus (CMV) infection compromises immune control of Mycobacterium tuberculosis (MTB), the pathogen causing tuberculosis. The research employs a murine co-infection...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $205,216 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize proteins required for Mycobacterium tuberculosis heme degradation. The research aims to identify additional proteins in the MTB heme catabolism pathway beyond the known MHUD protein, which catalyzes iron release from heme. The project will investigate the fate of MHUD...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Irvine $141,712 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize a novel histidine phosphotransfer system involved in the virulence of Mycobacterium tuberculosis. The funded research investigates how virulence-associated dikinase (VADK) coordinates metabolism and virulence in MTB by interacting with partner proteins. The work combines...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, Davis $404,108 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, for research aimed at identifying the determinants of persister cell survival in Mycobacterium tuberculosis (MTB). The research will deliver scientific insights through two primary research aims: (1) rigorous genetic identification of the determinants enabling persister...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of California, doing business as University of California, Berkeley, $756,714 under Project Grant R01AI197387 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research investigating the interplay of protein secretion and lipid virulence factors in host immune suppression by Mycobacterium tuberculosis. The work examines two critical virulence...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $673,851 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop broad-spectrum inhibitors of serine and metallo carbapenemases targeting ESKAPE pathogens. The recipient will optimize a novel family of cross-class carbapenemase inhibitors to nominate one or more development candidates ready for IND-enabling studies. The...
- The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $150,104 on January 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to explore leaderless mRNA translation in mycobacteria as a potential drug target for tuberculosis treatment. The research comprises three aims investigating how mycobacterial ribosomes translate leaderless mRNAs—transcripts lacking the 5' untranslated region and...
- The National Institute of Allergy and Infectious Diseases awarded the University of California Santa Cruz $259,415 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine the functional role of long non-coding RNAs (lncRNAs) in tuberculosis infection within macrophages. The research investigates post-transcriptional regulatory mechanisms that control innate immune response to Mycobacterium tuberculosis. The work follows preliminary screening of...